Elsevier

Journal of Infection

Volume 81, Issue 2, August 2020, Pages 318-356
Journal of Infection

Letters to the Editor
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

https://doi.org/10.1016/j.jinf.2020.04.017Get rights and content

Highlights

  • Baricitinib at 4 mg/day/orally was given to 12 patients with moderate COVID-19.

  • In baricitinib-treated patients no adverse events were recorded, after 2 weeks.

  • Clinical and respiratory parameters significantly improved at 2 weeks.

  • None of the baricitinib-treated patients required admission to ICU.

  • Proper control group was missing; this is required to demonstrate the efficacy.

Cited by (0)

View Abstract